Page last updated: 2024-10-31

nafamostat and Bone Neoplasms

nafamostat has been researched along with Bone Neoplasms in 1 studies

nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic

Bone Neoplasms: Tumors or cancer located in bone tissue or specific BONES.

Research Excerpts

ExcerptRelevanceReference
"Bone metastases from gastric cancer (GC) are considered a relatively uncommon finding; however, they are related to poorer prognosis."2.52Targeting mast cells in gastric cancer with special reference to bone metastases. ( Ammendola, M; De Sarro, G; Gadaleta, CD; Leporini, C; Marech, I; Oakley, C; Ranieri, G; Russo, E; Sacco, R; Sammarco, G, 2015)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Leporini, C1
Ammendola, M1
Marech, I1
Sammarco, G1
Sacco, R1
Gadaleta, CD1
Oakley, C1
Russo, E1
De Sarro, G1
Ranieri, G1

Reviews

1 review available for nafamostat and Bone Neoplasms

ArticleYear
Targeting mast cells in gastric cancer with special reference to bone metastases.
    World journal of gastroenterology, 2015, Oct-07, Volume: 21, Issue:37

    Topics: Animals; Antigens, CD34; Benzamides; Benzamidines; Bone and Bones; Bone Neoplasms; Bone Resorption;

2015